Barclays Increases Pfizer Price Target
In a report released Wednesday, Barclays analyst Mark Purcell increases his price target for Pfizer (NYSE: PFE) from $32 to $34 per share, maintaining an Equal-Weight rating.
Analyst at Barclays are more bullish on the pharmaceutical sector, favoring Pfizer's potential for organic growth. Purcell mentions Pfizer's near-term potential depends on the company's ability to change its tax structure, increase transactions through core operations and increase its pipeline to full potential.
Shares of Pfizer are up about one percent.
Latest Ratings for PFE
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.